Aaron Wealth Makes a Big Bet on MBX Biosciences With a 1.1 Million Share Purchase
Key Points
Aaron Wealth Advisors LLC bought 1,098,176 shares of MBX Biosciences; estimated transaction value $37.35 million based on quarterly average pricing
Quarter-end position value increased by $32.66 million, reflecting both trading and stock price movement
Trade represented 2.12% of fund’s 13F reportable assets under management
Post-trade, the fund held 1,168,176 shares valued at $34.87 million
The position now accounts for 1.98% of fund AUM, which places it outside the fund's top five holdings
- 10 stocks we like better than Mbx Biosciences ›
What happened
According to a filing with the Securities and Exchange Commission dated April 21, 2026, Aaron Wealth Advisors LLC bought 1,098,176 shares of MBX Biosciences (NASDAQ:MBX) during the first quarter. The estimated value of the trade was $37.35 million, based on the average closing price during the quarter. The quarter-end value of the position rose by $32.66 million, a figure that incorporates both the net purchase and changes in the share price.
What else to know
- This was a buy; the MBX Biosciences stake represents 1.98% of Aaron Wealth Advisors LLC’s 13F reportable assets after the filing.
- Top holdings after the filing:
- NYSEMKT: IEFA: $139.12 million (8.0% of AUM)
- NASDAQ: VONV: $101.89 million (5.9% of AUM)
- NASDAQ: VONG: $94.67 million (5.5% of AUM)
- NASDAQ: NVDA: $84.44 million (4.9% of AUM)
- NYSE: SGOV: $65.17 million (3.8% of AUM)
- As of April 20, 2026, MBX Biosciences shares were priced at $33.78, up 342.1% over the past year, outperforming the S&P 500 by 308.73 percentage points on a price-change basis.
Company overview
| Metric | Value |
|---|---|
| Price (as of market close April 20, 2026) | $33.78 |
| Market capitalization | $1.61 billion |
| Net income (TTM) | ($86.97 million) |
| One-year price change | 342.1% |
Company snapshot
- MBX Biosciences develops precision peptide therapies targeting endocrine and metabolic disorders, with a pipeline including MBX 2109 (Phase 2 for chronic hypoparathyroidism), MBX 1416 (Phase 1 for post-bariatric hypoglycemia), and MBX 4291 (preclinical for obesity and related comorbidities).
- The company operates a clinical-stage biopharmaceutical business model, generating value through the discovery, development, and potential future commercialization or licensing of proprietary drug candidates.
- Headquartered in Carmel, Indiana, MBX Biosciences employs 43 people and focuses on addressing unmet medical needs in orphan and specialty disease markets.
MBX Biosciences is a clinical-stage biotechnology company focused on advancing novel peptide therapeutics for complex endocrine and metabolic conditions. The company leverages expertise in precision peptide engineering to address unmet medical needs, with a strategic emphasis on differentiated, long-acting therapies. Its pipeline and specialized approach position it to compete in high-value orphan and specialty disease markets.
What this transaction means for investors
Aaron Wealth Advisors expanded its MBX Biosciences position from 70,000 shares at the end of 2025 to 1,168,176 shares during the first quarter of 2026. Unfortunately for the fund, the stock has only gained about 7% this year.
It appears that Aaron Wealth is bullish for MBX Biosciences’ lead candidate, canvuparatide. In March, the company told investors the Food and Drug Administration provided feedback supporting the company’s planned phase 3 trial.
MBX Biosciences intends to begin a phase 3 study with canvuparatide in the third quarter. The parathyroid hormone peptide prodrug is designed to be a long-acting replacement treatment for people with hypoparathyroidism.
Last September, MBX Biosciences announced successful results from a phase 2 study with canvuparatide. A weekly subcutaneous injection significantly improved patients’ ability to maintain normal blood calcium levels without help from conventional treatments.
MBX Biosciences intends to enroll about 160 patients and run them through 26 weeks of treatment and observation. Patients achieving normal calcium levels and independence from conventional therapy are the primary endpoints for the pivotal trial.
Should you buy stock in Mbx Biosciences right now?
Before you buy stock in Mbx Biosciences, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Mbx Biosciences wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $499,277!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,225,371!*
Now, it’s worth noting Stock Advisor’s total average return is 972% — a market-crushing outperformance compared to 198% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of April 22, 2026.
Cory Renauer has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Nvidia and iShares Trust - iShares 0-3 Month Treasury Bond ETF. The Motley Fool has a disclosure policy.
Recommended Articles
